File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00264-018-4245-8
- Scopus: eid_2-s2.0-85057602136
- PMID: 30498908
- WOS: WOS:000462975000032
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Clinical trials of intervertebral disc regeneration: current status and future developments
Title | Clinical trials of intervertebral disc regeneration: current status and future developments |
---|---|
Authors | |
Keywords | Clinical trial ;;; Small molecule Growth factor Intervertebral disc degeneration Mesenchymal stromal cells Regeneration |
Issue Date | 2019 |
Publisher | Springer. The Journal's web site is located at http://www.springer.com/medicine/orthopedics/journal/264 |
Citation | International Orthopaedics, 2019, v. 43 n. 4, p. 1003-1010 How to Cite? |
Abstract | Intervertebral disc (IVD) degeneration (IDD) is considered as one of the major causes for low back pain (LBP). However, conventional surgical approaches for treating LBP do not aim to counter the degeneration. Biological interventions have been investigated with an attempt to regenerate the IVD by restoring its matrices and cell activities. This review summarizes the current clinical trials that explore the efficacy of covering cell-, growth factor-, and small molecule-based approaches. While investigations of growth factor- and small molecule-based therapies are still preliminary, intradiscal delivery of mesenchymal stromal cells has been more widely adopted and shown positive results in addressing the pain and the associated physical disability, albeit to a lower extent than observed in previous animal studies. Strategies that potentiate the endogenous disc progenitors may offer a valid alternative to the exogenous cell transplantation. Identification of the novel biologics to arrest IDD phenotype may potentiate disc repair in future. Large-scale, high-quality long-term trials should be conducted to clarify the safety and efficacy of these therapies. |
Persistent Identifier | http://hdl.handle.net/10722/269582 |
ISSN | 2023 Impact Factor: 2.0 2023 SCImago Journal Rankings: 0.877 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sun, Y | - |
dc.contributor.author | Leung, VYL | - |
dc.contributor.author | Cheung, KMC | - |
dc.date.accessioned | 2019-04-24T08:10:36Z | - |
dc.date.available | 2019-04-24T08:10:36Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | International Orthopaedics, 2019, v. 43 n. 4, p. 1003-1010 | - |
dc.identifier.issn | 0341-2695 | - |
dc.identifier.uri | http://hdl.handle.net/10722/269582 | - |
dc.description.abstract | Intervertebral disc (IVD) degeneration (IDD) is considered as one of the major causes for low back pain (LBP). However, conventional surgical approaches for treating LBP do not aim to counter the degeneration. Biological interventions have been investigated with an attempt to regenerate the IVD by restoring its matrices and cell activities. This review summarizes the current clinical trials that explore the efficacy of covering cell-, growth factor-, and small molecule-based approaches. While investigations of growth factor- and small molecule-based therapies are still preliminary, intradiscal delivery of mesenchymal stromal cells has been more widely adopted and shown positive results in addressing the pain and the associated physical disability, albeit to a lower extent than observed in previous animal studies. Strategies that potentiate the endogenous disc progenitors may offer a valid alternative to the exogenous cell transplantation. Identification of the novel biologics to arrest IDD phenotype may potentiate disc repair in future. Large-scale, high-quality long-term trials should be conducted to clarify the safety and efficacy of these therapies. | - |
dc.language | eng | - |
dc.publisher | Springer. The Journal's web site is located at http://www.springer.com/medicine/orthopedics/journal/264 | - |
dc.relation.ispartof | International Orthopaedics | - |
dc.rights | This is a post-peer-review, pre-copyedit version of an article published in International Orthopaedics. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00264-018-4245-8 | - |
dc.subject | Clinical trial ;;; Small molecule | - |
dc.subject | Growth factor | - |
dc.subject | Intervertebral disc degeneration | - |
dc.subject | Mesenchymal stromal cells | - |
dc.subject | Regeneration | - |
dc.title | Clinical trials of intervertebral disc regeneration: current status and future developments | - |
dc.type | Article | - |
dc.identifier.email | Sun, Y: hkusunyi@hku.hk | - |
dc.identifier.email | Leung, VYL: vicleung@hku.hk | - |
dc.identifier.email | Cheung, KMC: cheungmc@hku.hk | - |
dc.identifier.authority | Leung, VYL=rp01764 | - |
dc.identifier.authority | Cheung, KMC=rp00387 | - |
dc.description.nature | postprint | - |
dc.identifier.doi | 10.1007/s00264-018-4245-8 | - |
dc.identifier.pmid | 30498908 | - |
dc.identifier.scopus | eid_2-s2.0-85057602136 | - |
dc.identifier.hkuros | 297453 | - |
dc.identifier.volume | 43 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 1003 | - |
dc.identifier.epage | 1010 | - |
dc.identifier.isi | WOS:000462975000032 | - |
dc.publisher.place | Germany | - |
dc.identifier.issnl | 0341-2695 | - |